Research coauthored by RTI Health Solutions will be presented at AMCP 2024. If you are attending, please stop by our posters and see our research on Avelumab therapy and Fetal and neonatal alloimmune thrombocytopenia.
Budget impact analysis of VOWST ™ oral spores (VOS, Formerly SER-109) for prevention of recurrent clostridioides difficile infection in the United States (US). Golan Y, Amin AN, Dubberke ER, Wilson M, Nguyen D, Kvasz M.
Poster Presentation: A1
9:30-11 am, CT
April 16, 2024
Avelumab first-line maintenance (1LM) therapy for locally advanced/metastatic urothelial carcinoma (la/mUC): Results from the realworld US PATRIOT-II study. Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg C, Brown J, Dave V, Downey C, Shillington A, Katzenstein H, Kirker M, Hanson S, Liu F, Morris V, Bhanegaonkar A, Sonpavde G.
Poster Presentation: C27
9:30-11 am, CT
April 16, 2024
Fetal and neonatal alloimmune thrombocytopenia: a systematic literature review and meta-analysis of adverse pregnancy-related outcomes to support the development of a novel prophylactic therapeutic. Margulis AV, Riera-Guardia N, Calingaert B, Armstrong R, Fletcher M, Patki K, Weiner E, Rivero-Ferrer E.
Poster Presentation: P1
1:00-2:30 pm, CT
April 16, 2024
#AMCP2024
